In a prespecified exploratory analysis, we considered the benefit of capivasertib by tumour PI3K/AKT/PTEN pathway-altered status after expanding testing of the originally collected tumour or plasma samples to include NGS assays. The gene discussed is AKT1; the disease is neoplasm.